Back to News
Market Impact: 0.2
Rewind Therapeutics Secures Additional Financing to Advance Oral GPR17 Remyelination Program
Source: GlobeNewswire
Healthcare & BiotechPrivate Markets & Venture
Rewind Therapeutics secured financing to advance its oral GPR17 remyelination program for multiple sclerosis. The program is supported by peer-reviewed preclinical data published in PLOS ONE; the article provides no financing amount or clinical-stage results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Why is Telix Pharmaceuticals stock rallying today?
- DeepSeek considers doubling latest funding round to up to $15 billion, sources say
- Anduril lands $2.9 billion Navy submarine shipyard contract days after CEO joins Pentagon weapons group
- SpaceX seeks $40 billion to buy Nvidia chips, FT reports
- Apollo’s Zelter Says Compute, Energy Will Be AI Bottlenecks
- Mistral unveils new AI model it says rivals best open systems from China